Status:
COMPLETED
Combination Therapy of Hydroxyurea With L-Carnitine and Magnesium Chloride in Thalassemia Intermedia
Lead Sponsor:
Shiraz University of Medical Sciences
Conditions:
β-Thalassemia Intermedia
Eligibility:
All Genders
4-35 years
Phase:
PHASE2
Brief Summary
The purpose of this study is determination of the efficacy of combination of hydroxyurea with L-carnitine or magnesium in improving hematologic parameters and cardiac status in patients with β-thalass...
Eligibility Criteria
Inclusion
- Beta thalassemia intermedia patients with mean hemoglobin level \>= 7gr/dl, need to blood transfusion with more than 6 months interval or no need to blood transfusion
Exclusion
- Hypothyroidism
- Hypoparathyroidism
- Diabetes mellitus
- Hepatitis B and C
- Positive tests for human immunodeficiency virus
- Any cardiac symptoms or receiving drug for cardiac disease
- Presence of other hemoglobinopathies except thalassemia intermedia and pregnant or lactating womens
Key Trial Info
Start Date :
June 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2007
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT00809042
Start Date
June 1 2007
End Date
December 1 2007
Last Update
December 16 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hematology Research Center of Shiraz University of Medical Sciences
Shiraz, Fars, Iran